J Haem Pract 2015; 2(2):3-4. doi: 10.17225/jhp00048

Authors: Edward Tuddenham

Professor Edward Tuddenham
Emeritus Professor of Haemophilia
University College, London, Gower St, London WC1E 6BT, UK. Email:


Use of recombinant clotting factor now represents the standard of care in haemophilia across the developed world. But the recombinant era would not have occurred without the isolation from plasma of factor VIII in sufficient quantities to allow characterisation and cloning. Much of this development work occurred at the Royal Free Hospital.




  1. Zimmerman TS, Ratnoff OD, Powell AE. Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand’s disease, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor. J Clin Invest 1971; 50(1): 244-54.
  2. Owen WG, Wagner RH. Thromb Diath Haemorrh 1972; 27(3): 502-15.
  3. Vehar GA, Keyt B, Eaton D, et al. Structure of human factor VIII. Nature 1984; 312(5992): 337-42.
  4. Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312(5992): 330-7.
  5. Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature 1984; 312(5992): 326-30.
  6. Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312(5992): 342-7.

The Journal of Haemophilia Practice is published by Haemnet.

Haemnet is a registered charity that brings together and gives a voice to haemophilia nurses, physiotherapists and allied health care professionals, providing forums for collaborative research, educational activities and support.